The director of Galectin Therapeutics, Inc. (GALT), Theodore Zucconi Sold 4,000 Shares of the Company; Rait Financial Trust (RAS)’s Sentiment Is 1.34

Galectin Therapeutics, Inc. (NASDAQ:GALT) Logo

Rait Financial Trust (RAS) investors sentiment increased to 1.34 in 2017 Q4. It’s up 0.87, from 0.47 in 2017Q3. The ratio is positive, as 43 investment professionals opened new and increased stock positions, while 32 sold and trimmed equity positions in Rait Financial Trust. The investment professionals in our database now have: 37.50 million shares, down from 47.82 million shares in 2017Q3. Also, the number of investment professionals holding Rait Financial Trust in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 11 Reduced: 21 Increased: 23 New Position: 20.

The director of Galectin Therapeutics Inc, Theodore Zucconi is in the stock market news today. It was stated in a public document filled by Theodore Zucconi and submitted to the SEC on April 18, 2018, he sold 4,000 shares from the ‘s company having a total value of $14,320 U.S. Dollars. Theodore Zucconi’s shares average price was $3.6. Currently, Mr. Theodore, has 1,083 shares, which accounts for 0.00% of the Company’s market cap.

Analysts await Galectin Therapeutics, Inc. (NASDAQ:GALT) to report earnings on May, 21. They expect $-0.13 earnings per share, up 13.33% or $0.02 from last year’s $-0.15 per share. After $-0.07 actual earnings per share reported by Galectin Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 85.71% negative EPS growth.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $126.61 million. The companyÂ’s lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

Since January 25, 2018, it had 2 insider buys, and 3 insider sales for $2.66 million activity. The insider CZIRR JAMES C sold $1.33 million. On Thursday, January 25 10X Fund – L.P. sold $1.33 million worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) or 244,444 shares. 3,349 Galectin Therapeutics, Inc. (NASDAQ:GALT) shares with value of $16,745 were sold by CALLICUTT JACK W. Shares for $8,191 were bought by FREEMAN KEVIN D.

The stock decreased 2.60% or $0.09 during the last trading session, reaching $3.37. About 589,872 shares traded or 9.91% up from the average. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 77.90% since April 19, 2017 and is uptrending. It has outperformed by 66.35% the S&P500.

Among 5 analysts covering Galectin Therapeutics (NASDAQ:GALT), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Galectin Therapeutics has $8 highest and $0.75 lowest target. $4.63’s average target is 37.39% above currents $3.37 stock price. Galectin Therapeutics had 12 analyst reports since September 21, 2015 according to SRatingsIntel. The rating was reinitiated by H.C. Wainwright with “Buy” on Monday, March 28. The rating was downgraded by H.C. Wainwright on Thursday, September 29 to “Neutral”. The company was downgraded on Wednesday, September 28 by TH Capital. FBR Capital downgraded Galectin Therapeutics, Inc. (NASDAQ:GALT) rating on Monday, October 3. FBR Capital has “Mkt Perform” rating and $2 target. The rating was upgraded by H.C. Wainwright to “Buy” on Thursday, March 30. Roth Capital downgraded Galectin Therapeutics, Inc. (NASDAQ:GALT) on Wednesday, September 28 to “Sell” rating. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) has “Buy” rating given on Wednesday, June 14 by H.C. Wainwright. The rating was initiated by H.C. Wainwright on Monday, September 21 with “Buy”. Roth Capital maintained Galectin Therapeutics, Inc. (NASDAQ:GALT) rating on Thursday, January 4. Roth Capital has “Buy” rating and $8.0 target. The firm has “Buy” rating by Roth Capital given on Thursday, December 7.

Investors sentiment decreased to 0.53 in 2017 Q4. Its down 0.14, from 0.67 in 2017Q3. It dropped, as 6 investors sold Galectin Therapeutics, Inc. shares while 13 reduced holdings. 7 funds opened positions while 3 raised stakes. 3.08 million shares or 4.50% less from 3.22 million shares in 2017Q3 were reported. Courage Limited Liability, Tennessee-based fund reported 50,000 shares. Guggenheim Capital Llc owns 10,390 shares or 0% of their US portfolio. Bank & Trust Of America De has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Neuberger Berman Ltd Liability Corporation stated it has 82,494 shares. Northern owns 83,668 shares for 0% of their portfolio. Wells Fargo And Mn accumulated 10,882 shares or 0% of the stock. Raymond James Assocs stated it has 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). The Massachusetts-based Geode Limited Liability Company has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Pnc Services Grp holds 51,184 shares or 0% of its portfolio. Art Lc invested 0.01% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). Us Commercial Bank De holds 118,921 shares or 0% of its portfolio. Moreover, Riggs Asset Managment Incorporated has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 1,000 shares. Norris Perne And French Llp Mi holds 0.01% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 30,500 shares. Dynamic Advsr Solutions Lc owns 10,000 shares. Goldman Sachs reported 12,528 shares.

RAIT Financial Trust operates as a self-managed and self-advised real estate investment trust . The company has market cap of $18.95 million. The company, through its subsidiaries, invests in, manages, and services real estate-related assets with a focus on commercial real estate. It currently has negative earnings. It also offers a set of debt financing options to the commercial real estate industry along with fixed income trading and advisory services.

The stock increased 12.29% or $0.0223 during the last trading session, reaching $0.2037. About 6.22M shares traded or 99.10% up from the average. RAIT Financial Trust (RAS) has declined 93.53% since April 19, 2017 and is downtrending. It has underperformed by 105.08% the S&P500.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Positions Chart